Sydney Local Health District

Winner: Health Research Award

 

ANZAC Institute at Concord Hospital in Sydney Local Health District (SLHD) are working to empower people living with diabetes by expanding their treatment options. The team has developed oral insulin, offering a new alternative where only injection treatments were previously available.

The pre-clinical work outlining this technology was published in Nature Nanotechnology research journal. This led to an exclusive on Channel 9 News Australia and more than 60 news articles worldwide in over 18 different languages.

The team has undertaken rigorous basic and translational research to develop a novel nanotechnology-based delivery platform. This provides an oral insulin formulation to treat insulin dependent diabetes.

Oral insulin has undergone wide-ranging preclinical testing and is now in production in preparation for clinical trial in early 2025. The team seek to improve the treatment of diabetes and prevent the significant long-term impact of this disease.​​

​​​​​​​​​​​​​

Current as at: Thursday 24 October 2024